Trazodone: properties and utility in multiple disorders

References

• Sweetman S. Trazodone. In: Martindale: The Complete Drug Reference. Sweetman S (Ed.). Pharmaceutical Press, Micromedex Inc., CO, USA (2009).
   Google Scholar
• Box KJ, Völgyi G, Baka E, Stuart M, Takács-Novák K, Comer JE. Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution – a validation study. J. Pharm. Sci.95(6), 1298–1307 (2006).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr.14(10), 536–546 (2009).
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Savage JE et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation102(23), 2836–2841 (2000).
   PubMed Web of Science ®Google Scholar
• Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTP γ-S binding. J. Psychopharmacol.19(3), 235–241 (2005).
   PubMed Web of Science ®Google Scholar
• Chanrion B, Mannoury la Cour C et al. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol. Pharmacol.73(3), 748–757 (2008).
   PubMed Web of Science ®Google Scholar
• Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging4(4), 331–355 (1994).
   PubMed Web of Science ®Google Scholar
• Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther.283(3), 1305–1322 (1997).
   PubMed Web of Science ®Google Scholar
• Stanton T, Bolden-Watson C, Cusack B, Richelson E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem. Pharmacol.45(11), 2352–2354 (1993).
   PubMed Web of Science ®Google Scholar
• Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature261(5562), 717–719 (1976).
   PubMed Web of Science ®Google Scholar
• Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl).114(4), 559–565 (1993).
   Google Scholar
• Balsara JJ, Jadhav SA, Gaonkar RK, Gaikwad RV, Jadhav JH. Effects of the antidepressant trazodone, a 5-HT2A/2C receptor antagonist, on dopamine-dependent behaviors in rats. Psychopharmacology (Berl).179(3), 597–605 (2005).
   PubMedGoogle Scholar
• Millan MJ, Lejeune F, Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol.14(2), 114–138 (2000).
   PubMed Web of Science ®Google Scholar
• Luparini MR, Garrone B, Pazzagli M et al. A cortical GABA–5HT interaction in the mechanism of action of the antidepressant trazodone. Prog. Neuropsychopharmacol. Biol. Psychiatry28(7), 1117–1127 (2005).
   Google Scholar
• Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology (Berl).144(3), 220–233 (1999).
   PubMed Web of Science ®Google Scholar
• Kraus RL, Li Y, Jovanovska A, Renger JJ. Trazodone inhibits T-type calcium channels. Neuropharmacology53(2), 308–317 (2007).
   PubMed Web of Science ®Google Scholar
• Belardetti F, Zamponi GW. Linking calcium-channel isoforms to potential therapies. Curr. Opin. Investig. Drugs9(7), 707–715 (2008).
   PubMed Web of Science ®Google Scholar
• Monteleone P, Delrio G. Pharmacokinetic and pharmacodynamic characteristics of a controlled release formulation of trazodone versus the conventional formulation in healthy volunteers. Ital. J. Neurol. Sci.14(6), 443–449 (1993).
   PubMedGoogle Scholar
• Karhu D, Groenewoud G, Potgieter L, Mould DR. Dose proportionality of once-daily trazodone extended-release caplets under fasting conditions. J. Clin. Pharmacol.50(12), 1438–1449 (2010).
   PubMed Web of Science ®Google Scholar
• Roth BL, Lopez E, Beischel S, Westkaemper RB, Evans JM. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol. Ther.102(2), 99–110 (2004).
   PubMed Web of Science ®Google Scholar
• Baumann MH, Ayestas MA, Dersch CM, Rothman RB. 1-(m-chlorophenyl) piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacol.24(5), 492–501 (2001).
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Blough BE, Jacobson AE, Rice KC, Partilla JS. Evidence for noncompetitive modulation of substrate-induced serotonin release. Synapse64(11), 862–869 (2010).
   PubMedGoogle Scholar
• Cole JC, Sumnall HR. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci. Biobehav. Rev.27(3), 199–217 (2003).
   PubMed Web of Science ®Google Scholar
• Tancer M, Johanson CE. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend.72(1), 33–44 (2003).
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Friedman H, Burstein ES et al. Trazodone kinetics: effect of age, gender, and obesity. Clin. Pharmacol. Ther.42(2), 193–200 (1987).
   PubMed Web of Science ®Google Scholar
• Nilsen OG, Dale O. Single dose pharmacokinetics of trazodone in healthy subjects. Pharmacol. Toxicol.71(2), 150–153 (1992).
   PubMedGoogle Scholar
• Ankier SI, Warrington SJ, Sneddon JM. A pharmacokinetic and dynamic study of single nightly doses of conventional and controlled release formulations of trazodone. Methods Find Exp. Clin. Pharmacol.13(2), 121–127 (1991).
   PubMedGoogle Scholar
• Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab. Dispos.26(6), 572–575 (1998).
   PubMed Web of Science ®Google Scholar
• Zalma A, von Moltke LL, Granda BW, Harmatz JS, Shader RI, Greenblatt DJ. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol. Psychiatry47(7), 655–661 (2000).
   PubMed Web of Science ®Google Scholar
• Wen B, Ma L, Rodrigues AD, Zhu M. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab. Dispos.36(5), 841–850 (2008).
   PubMed Web of Science ®Google Scholar
• Bayer AJ, Pathy MS, Ankier SI. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly. Br. J. Clin. Pharmacol.16(4), 371–376 (1983)
   PubMed Web of Science ®Google Scholar
• Otani K, Mihara K, Yasui N et al. Plasma concentrations of trazodone and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone. Prog. Neuropsychopharmacol. Biol. Psychiatry21(1), 239–244 (1997).
   PubMed Web of Science ®Google Scholar
• Nilsen OG, Dale O, Husebø B. Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. Pharmacol. Toxicol.72(4–5), 286–289 (1993).
   PubMedGoogle Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J. Clin. Pharmacol.43(4), 414–422 (2003).
   PubMed Web of Science ®Google Scholar
• Lawlor BA, Radcliffe J, Martinez R, Sunderland T, Murphy DL. Plasma levels of m-chlorophenylpiperazine following single oral dose administration of m-chlorophenylpiperazine and trazodone in human volunteers. Biol. Psychiatry41(6), 756–757 (1997).
   PubMedGoogle Scholar
• Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology (Berl).98(2), 275–282 (1989).
   PubMedGoogle Scholar
• Feuchtl A, Bagli M, Stephan R et al. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry37(4), 180–188 (2004).
   PubMed Web of Science ®Google Scholar
• Mihara K, Yasui-Furukori N, Kondo T et al. Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients. Therap. Drug Monit.24(4), 563–566 (2002).
   PubMed Web of Science ®Google Scholar
• Caccia S, Ballabio M, Fanelli R et al. Determination of plasma and brain concentrations of trazodone and its metabolite, 1-m-chlorophenylpiperazine, by gas-liquid chromatography. J. Chromatogr.210(2), 311–318 (1981).
   PubMedGoogle Scholar
• Tollefson GD, Saxena S, Luxenberg M, Garvey MJ. A retrospective evaluation of plasma trazodone concentrations and clinical response in a primary care clinic. Hillside J. Clin. Psychiatry10(2), 183–187 (1988).
   PubMedGoogle Scholar
• Monteleone P, Gnocchi G. Evidence for a linear relationship between plasma trazodone levels and clinical response in depression in the elderly. Clin. Neuropharmacol.13(Suppl. 1), S84–S89 (1990).
   PubMedGoogle Scholar
• Brewerton TD, Murphy DL, Mueller EA, Jimerson DC. Induction of migraine-like headaches by the serotonin agonist m-chlorophenylpiperazine. Clin. Pharmacol. Ther.43(6), 605–609 (1988).
   PubMed Web of Science ®Google Scholar
• Debbas NM, Ankier SI, Warrington SJ. Trazodone conventional and controlled-release formulations: pharmacodynamic effects after single and repeated administration. Curr. Med. Res. Opin.11(8), 501–509 (1989).
   PubMed Web of Science ®Google Scholar
• Ellenhorn MJ. Antidepressants. In: Ellenhorn’s Medical Toxicology: Diagnosis and Treatment of Human Poisoning. Ellenhorn MJ, Schonwald S, Ordog G, Wasserberger J (Eds). Williams and Wilkins, MD, USA, 619 (1996).
   Google Scholar
• Longmore J, Banjar W, Bradshaw CM, Szabadi E. Effects of a controlled-release formulation of trazodone on psychomotor and autonomic functions in healthy volunteers: comparison with trazodone (conventional formulation), amitriptyline and placebo. Eur. J. Clin. Pharmacol.34(1), 97–99 (1988).
   PubMedGoogle Scholar
• Berendsen HG, Jenck F, Broekkamp CLE. Involvement of 5-HT1C receptors in drug-induced penile erections in rats. Psychopharmacology (Berl).101(1), 57–61 (1990).
   PubMedGoogle Scholar
• Silverstone PH, Rue JE, Franklin M et al. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. Int. Clin. Psychopharmacol.9(3), 173–178 (1994).
   PubMed Web of Science ®Google Scholar
• Broocks A, Pigott TA, Hill JL et al. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. Psychiatry Res.79(1), 11–20 (1998).
   PubMedGoogle Scholar
• Benjamin J, Greenberg BD, Murphy DL. Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psychopharmacology (Berl).127(2), 140–149 (1996).
   PubMed Web of Science ®Google Scholar
• Ceulemans DLS, Hoppenbrouwers MLJA, Gelders YG. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind, placebo-controlled study versus lorazepam. Pharmacopsychiatry18(5), 303–305 (1985).
   PubMed Web of Science ®Google Scholar
• Kennett GA, Lightowler S, Debiasi V. Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT-2C/2B receptor function. Neuropharmacology33(12), 1581–1588 (1994).
   PubMedGoogle Scholar
• Swinney DC. Applications of binding kinetics to drug discovery: translation of binding mechanisms to clinically differentiated therapeutic responses. Pharm. Med.22(1), 23–34 (2008).
   Google Scholar
• Roemer RA, Richelson E, Shagass C, Leventhal L. A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs. J. Psychiatry Neurosci.21(5), 325–333 (1996).
   PubMedGoogle Scholar
• Golden RN, Dawkins K, Nicholas L. Trazodone and nefazodone. In: Textbook of Psychopharmacology (4th Edition). Schatzberg AF, Nemeroff CB (Eds). The American Psychiatric Publishing, Washington, DC, USA, 403–407 (2009).
   Google Scholar
• Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann. Clin. Psych.18(1), 49–56 (2006).
   PubMedGoogle Scholar
• James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J. Clin. Psychiatry65(6), 752–755 (2004).
   PubMed Web of Science ®Google Scholar
• Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J. Clin. Psychiatry66(4), 469–476 (2005).
   PubMed Web of Science ®Google Scholar
• Lelkes Z, Obál F Jr, Alföldi P, Erdös A, Rubicsek G, Benedek G. Effects of acute and chronic treatment with trazodone, an antidepressant, on the sleep-wake activity in rats. Pharmacol. Res.30(2), 105–115 (1994).
   PubMedGoogle Scholar
• Paterson LM, Wilson SJ, Nutt DJ, Hutson PH, Ivarsson M. A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers. Psychopharmacology (Berl).191(4), 943–950 (2007).
   PubMedGoogle Scholar
• Veasey SC, Fenik P, Panckeri K, Pack AI, Hendricks JC. The effects of trazodone with l-tryptophan on sleep-disordered breathing in the English bulldog. Am. J. Respir. Crit. Care Med.160(5 Pt 1), 1659–1667 (1999).
   PubMed Web of Science ®Google Scholar
• Lawlor BA, Newhouse PA, Balkin TJ et al. A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers. Biol. Psychiatry29(3), 281–286 (1991).
   PubMedGoogle Scholar
• Aton SJ, Seibt J, Dumoulin MC, Coleman T, Shiraishi M, Frank MG. The sedating antidepressant trazodone impairs sleep-dependent cortical plasticity. PLoS One4(7), e6078 (2009).
   PubMedGoogle Scholar
• Traber J, Glaser T. 5-HT-1A receptor-related anxiolytics. TIPS8(11), 432–437 (1987).
   Web of Science ®Google Scholar
• Soderpalm B, Lundin B, Hjorth S. Sustained 5-HT-release-inhibitory and anxiolytic-like action of the partial 5-HT-1A receptor agonist, buspirone, after prolonged chronic administration. Eur. J. Pharmacol.239(1–3), 69–73 (1993).
   PubMedGoogle Scholar
• Ramboz S, Oosting R, Amara DA et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl Acad. Sci. USA95(24), 14476–14481 (1998).
   PubMed Web of Science ®Google Scholar
• Weisstaub NV, Zhou M, Lira A, Lambe E et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science313(5786), 536–540 (2006).
   PubMed Web of Science ®Google Scholar
• Sramek JJ, Frackiewicz EJ, Cutler NR. Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety. Clin. Ther.19(3), 498–506 (1997).
   PubMed Web of Science ®Google Scholar
• Tauscher J, Verhoeff NP, Christensen BK et al. Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET. Neuropsychopharmacol.24(5), 522–530 (2001).
   PubMed Web of Science ®Google Scholar
• Yoon HK, Yang JC, Lee HJ, Kim YK. The association between serotonin-related gene polymorphisms and panic disorder. J. Anxiety Disord.22(8), 1529–1534 (2008).
   PubMed Web of Science ®Google Scholar
• Seiden LS, Dahms JL, Shaughnessy RA. Behavioral screen for antidepressants: the effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule. Psychopharmacology (Berl).86(1–2), 55–60 (1985).
   PubMed Web of Science ®Google Scholar
• Bourin M, Colombel MC, Malinge M, Bradwejn J. Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity. J. Psychiatry Neurosci.16(4), 199–203 (1991).
   PubMed Web of Science ®Google Scholar
• Kumar A, Garg R, Kumar P. Nitric oxide modulation mediates the protective effect of trazodone in a mouse model of chronic fatigue syndrome. Pharmacol. Rep.60(5), 664–672 (2008).
   PubMedGoogle Scholar
• Kumar A, Garg R. Possible role of trazodone and imipramine in sleep deprivation-induced anxiety-like behavior and oxidative damage in mice. Methods Find. Exp. Clin. Pharmacol.31(6), 383–387 (2009).
   PubMedGoogle Scholar
• Mavissakalian M, Perel J, Bowler K, Dealy R. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am. J. Psychiatry144(6), 785–787 (1987).
   PubMed Web of Science ®Google Scholar
• Pigott TA, L’Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J. Clin. Psychopharmacol.12(3), 156–162 (1992).
   PubMed Web of Science ®Google Scholar
• Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch. Gen. Psychiatry50(11), 884–895 (1993).
   PubMed Web of Science ®Google Scholar
• Hertzberg MA, Feldman ME, Beckham JC, Davidson JR. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J. Clin. Psychopharmacol.16(4), 294–298 (1996).
   PubMed Web of Science ®Google Scholar
• Ashford JW, Miller, TW. Effects of trazodone on sleep in patients diagnosed with post-traumatic stress disorder (PTSD). J. Contemp. Psychother.26(3), 221–233 (1996).
   Google Scholar
• Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry34(4), 128–131 (2001).
   PubMed Web of Science ®Google Scholar
• Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol. Psychiatry30(11), 1139–1166 (1989).
   Google Scholar
• Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch. Gen. Psychiatry44(11), 946–951 (1987).
   PubMed Web of Science ®Google Scholar
• Hollander E, De Caria CM, Nitescu A. Serotonergic function in obsessive-compulsive disorder: behavioural and neuroendocrine to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch. Gen. Psychiat.49(1), 21–28 (1992).
   PubMed Web of Science ®Google Scholar
• Erzegovesi S, Martucci L, Henin M, Bellodi L. Low versus standard dose m-CPP challenge in obsessive-compulsive patients. Neuropsychopharmacol.24(1), 31–36 (2001).
   PubMedGoogle Scholar
• Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res.95(1–3), 158–168 (2007).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav. Brain Res.195(1), 98–102 (2008).
   PubMed Web of Science ®Google Scholar
• Celada P, Puig M, Amargós-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J. Psychiatry Neurosci.29(4), 252–265 (2004).
   PubMed Web of Science ®Google Scholar
• Stein DJ, Hemmings S, Moolman-Smook H, Audenaert K. 5-HT2A: its role in frontally mediated executive function and related psychopathology. CNS Spectr.12(7), 512–516 (2007).
   PubMed Web of Science ®Google Scholar
• Arnsten AFT. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl).174(1), 25–31 (2004).
   PubMed Web of Science ®Google Scholar
• American Medical Association. Trazodone. In: AMA Drug Evaluations Annual 1994. American Medical Association staff (Ed.). American Medical Association, IL, USA, 309 (1994).
   Google Scholar
• Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry197(3), 174–179 (2010).
   PubMed Web of Science ®Google Scholar
• Chow TW. Treatment approaches to symptoms associated with frontotemporal degeneration. Curr. Psychiatry Rep.7(5), 376–380 (2005).
   PubMedGoogle Scholar
• Rudissaar R, Pruus K, Vaarmann A et al. Acute trazodone and quipazine treatment attenuates apomorphine-induced aggressive behavior in male rats without major impact on emotional behavior or monoamine content post mortem. Pharmacol. Res.43(4), 349–358 (2001).
   PubMedGoogle Scholar
• Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am. J. Geriatr. Psychiatry5(1), 60–69 (1997).
   PubMed Web of Science ®Google Scholar
• Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement. Geriatr. Cogn. Disord.17(4), 355–359 (2004).
   PubMed Web of Science ®Google Scholar
• Mendez MF. Frontotemporal dementia: therapeutic interventions. Front Neurol. Neurosci.24, 168–78 (2009).
   PubMedGoogle Scholar
• Reavill C, Kettle A, Holland V, Riley G, Blackburn TP. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br. J. Pharmacol.126(3), 572–574 (1999).
   PubMed Web of Science ®Google Scholar
• Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem. Pharmacol.75(1), 34–56 (2008)
   PubMed Web of Science ®Google Scholar
• Janiri L, Hadjichristos A, Buonanno A, Rago R, Mannelli P, de Risio S. Adjuvant trazodone in the treatment of alcoholism: an open study. Alcohol33(4), 362–365 (1998).
   Google Scholar
• McMillen BA, Walter S, Williams HL, Myers RD. Comparison of the action of the 5-HT2 antagonists amperozide and trazodone on preference for alcohol in rats. Alcohol11(3), 203–206 (1994).
   PubMedGoogle Scholar
• Schreiber S, Backler MM, Herman I et al. Mianserin and trazodone significantly attenuate the intensity of opioid withdrawal symptoms in mice. Addict. Biol.8(1), 107–114 (2003).
   PubMedGoogle Scholar
• Le Bon O, Murphy JR, Staner L et al. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J. Clin. Psychopharmacol.23(4), 377–383 (2003).
   PubMed Web of Science ®Google Scholar
• Friedmann PD, Rose JS, Swift R, Stout RL, Millman RP, Stein MD. Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. Alcohol Clin. Exp. Res.32(9), 1652–1660 (2008).
   PubMed Web of Science ®Google Scholar
• Buydens-Branchey L, Branchey M, Fergeson P, Hudson J, McKernin C. Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics. Alcohol Clin. Exp. Res.21(2), 220–226 (1997).
   PubMedGoogle Scholar
• Pope HG Jr, Keck PE Jr, McElroy SL, Hudson JI. A placebo-controlled study of trazodone in bulimia nervosa. J. Clin. Psychopharmacol.9(4), 254–259 (1989).
   PubMed Web of Science ®Google Scholar
• Hudson JI, Pope HG Jr, Keck PE Jr, McElroy SL. Treatment of bulimia nervosa with trazodone: short-term response and long-term follow-up. Clin. Neuropharmacol.12(Suppl. 1), S38–S46 (1989); discussion S47–S49 (1989).
   PubMed Web of Science ®Google Scholar
• Solyom L, Solyom C, Ledwidge B. Trazodone treatment of bulimia nervosa. J. Clin. Psychopharmacol.9(4), 287–290 (1989).
   PubMedGoogle Scholar
• Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst. Rev.4, CD003391 (2003).
   PubMedGoogle Scholar
• Flament MF, Furino C, Dogart N. Evidence-based pharmacotherapy of eating disorder. In: Evidence-based Psychopharmacology. Stein DJ, Lerer B, Stahl SM (Eds). Cambridge University Press, London, UK, 204–254 (2005).
   Google Scholar
• Azadzoi KM, Payton T, Krane RJ, Goldstein I. Effects of intracavernosal trazodone hydrochloride: animal and human studies. J. Urol.144(5), 1277–1282 (1990).
   PubMedGoogle Scholar
• Andersson KE, Stief C. Oral α-adrenoceptor blockade as a treatment of erectile dysfunction. World J. Urol.19(1), 9–13 (2001).
   PubMedGoogle Scholar
• Kimura Y, Naitou Y, Wanibuchi F, Yamaguchi T. 5-HT(2C) receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in rats. Eur. J. Pharmacol.589(1–3), 157–162 (2008).
   PubMedGoogle Scholar
• Krege S, Goepel M, Sperling H, Michel MC. Affinity of trazodone for human penile α1- and α2-adrenoceptors. BJU Int.85(7), 959–961 (2000).
   PubMedGoogle Scholar
• Steers WD. Pharmacologic treatment of erectile dysfunction. Rev. Urol.4(Suppl. 3), S17–S25 (2002).
   PubMedGoogle Scholar
• Fink HA, MacDonald R, Rutks IR, Wilt TJ. Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int.92(4), 441–446 (2003).
   PubMed Web of Science ®Google Scholar
• Stryjer R, Spivak B, Strous RD et al. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin. Neuropharmacol.32(2), 82–84 (2009).
   PubMed Web of Science ®Google Scholar
• Pleger B, Ragert P. Pharmacological support of neurorehabilitation. Curr. Drug Ther.1, 17–22 (2006).
   Google Scholar
• Reding MJ, Orto LA, Winter SW, Fortuna IM, Di Ponte P, McDowell FH. Antidepressant therapy after stroke. A double-blind trial. Arch. Neurol.43(8), 763–765 (1986).
   PubMed Web of Science ®Google Scholar
• Ramirez-Lessepas M, Patrick BK, Snyder BD, Lakatua DJ. Failure of central nervous system serotonin blockage to influence outcome in acute cerebral infarction. A double blind randomized trial. Stroke17(5), 953–956 (1986).
   PubMedGoogle Scholar
• Miyai I, Reding MJ. Effects of antidepressants on functional recovery following stroke: a double-blind study. Neurorehabil. Neural. Repair12(1), 5–13 (1998).
   Google Scholar
• Berends HI, Nijlant JM, Movig KL, Van Putten MJ, Jannink MJ, Ijzerman MJ. The clinical use of drugs influencing neurotransmitters in the brain to promote motor recovery after stroke; a Cochrane systematic review. Eur. J. Phys. Rehabil. Med.45(4), 621–630 (2009).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Backer MM, Herman I, Shamir D, Boniel T, Pick CG. The antinociceptive effect of trazodone in mice is mediated through both µ-opioid and serotonergic mechanisms. Behav. Brain Res.114(1–2), 51–56 (2000).
   PubMed Web of Science ®Google Scholar
• Okuda K, Takanishi T, Yoshimoto K, Ueda S. Trazodone hydrochloride attenuates thermal hyperalgesia in a chronic constriction injury rat model. Eur. J. Anaesthesiol.20(5), 409–415 (2003).
   PubMedGoogle Scholar
• Zhang R, Nagata T, Hayashi T, Miyata M, Kawakami Y. Intracerebroventricular injection of trazodone produces 5-HT receptor subtype mediated anti-nociception at the supraspinal and spinal levels. Eur. Neuropsychopharmacol.14(5), 419–424 (2004).
   PubMedGoogle Scholar
• Frank RG, Beck NC, Parker JC, Kashani JH, Elliott TR, Haut AE. Depression in rheumatoid arthritis. J. Rheumatol.15(6), 920–925 (1988).
   PubMed Web of Science ®Google Scholar
• Davidoff G, Guarracini M, Roth E, Sliwa J, Yarkony G. Trazodone hydrochloride in the treatment of dysesthetic pain in traumatic myelopathy: a randomized, double-blind, placebo-controlled study. Pain29(2), 151–161 (1987).
   PubMed Web of Science ®Google Scholar
• Goodkin K, Gullion CM, Agras WS. A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome. J. Clin. Psychopharmacol.10(4), 269–278 (1990).
   PubMed Web of Science ®Google Scholar
• Wilson RC. The use of low-dose trazodone in the treatment of painful diabetic neuropathy. J. Am. Podiatr. Med. Assoc.89(9), 468–471 (1999).
   PubMed Web of Science ®Google Scholar
• Simmons Z, Feldman EL. The pharmacological treatment of painful diabetic neuropathy. Clin. Diabetes18(3), 116–118 (2000).
   Google Scholar
• Ventafridda V, Caraceni A, Saita L et al. Trazodone for deafferentation pain. Comparison with amitriptyline. Psychopharmacology (Berl).95(Suppl.), S44–S49 (1988).
   PubMedGoogle Scholar
• Molina-Barea R, Calandre E, Morillas-Arques P et al. Trazodone in the treatment of fibromyalgia: a 12 weeks open label study. Eur. Neuropsychopharmacol.18, S327–S328 (2008).
   Google Scholar
• Einarson A, Bonari L, Voyer-Lavigne S et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can. J. Psychiatry48(2), 106–110 (2003).
   PubMed Web of Science ®Google Scholar
• Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J. Clin. Pharm. Ther.30(2), 173–178 (2005).
   PubMed Web of Science ®Google Scholar
• Park KS, Kong ID, Park KC, Lee JW. Fluoxetine inhibits L-type Ca2+ and transient outward K+ currents in rat ventricular myocytes. Yonsei Med. J.40(2), 144–151 (1999).
   PubMed Web of Science ®Google Scholar
• Zitron E, Kiesecker C, Scholz E et al. Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. Naunyn Schmiedebergs Arch. Pharmacol.370(2), 146–156 (2004).
   PubMedGoogle Scholar
• Tarantino P, Appleton N, Lansdell K. Effect of trazodone on hERG channel current and QT-interval. Eur. J. Pharmacol.510(1–2), 75–85 (2005).
   PubMed Web of Science ®Google Scholar
• Redfern WS, Carlsson L, Davis AS et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsades de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res.58(1), 32–45 (2003).
   PubMed Web of Science ®Google Scholar
• Lisciani R, Baldini A, Benedetti D, Campana A, Barcellona PS. Acute cardiovascular toxicity of trazodone, etoperidone and imipramine in rats. Toxicology10(2), 151–158 (1978).
   PubMedGoogle Scholar
• Gomoll AW, Byrne JE, Deitchman D. Hemodynamic and cardiac actions of trazodone and imipramine in the anesthetized dog. Life Sci.24(20), 1841–1847 (1979).
   PubMed Web of Science ®Google Scholar
• Byrne JE, Gomoll AW. Differential effects of trazodone and imipramine on intracardiac conduction in the anesthetized dog. Arch. Int. Pharmacodyn. Ther.259(2), 259–270 (1982).
   PubMedGoogle Scholar
• Burgess CD, Hames TK, George CF. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man. Eur. J. Clin. Pharmacol.23(5), 417–421 (1982).
   PubMed Web of Science ®Google Scholar
• Shyu KG. Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? Circ. Res.104(1), 1–3, (2009).
   PubMed Web of Science ®Google Scholar
• Gamble DE, Peterson LG. Trazodone overdose: four years of experience from voluntary reports. J. Clin. Psychiatry47(11), 544–546 (1986).
   PubMed Web of Science ®Google Scholar
• Henry JA, Ali CJ, Caldwell R, Flanagan RJ. Acute trazodone poisoning: clinical signs and plasma concentrations. Psychopathology17(Suppl. 2), 77–81 (1984).
   PubMed Web of Science ®Google Scholar
• Flomenbaum N, Price D. Recognition and management of antidepressant overdoses: tricyclics and trazodone. Neuropsychobiology15(Suppl. 1), 46–51 (1986).
   PubMed Web of Science ®Google Scholar
• Goeringer KE, Raymon L, Logan BK: Postmortem forensic toxicology of trazodone. J. Forensic Sci.45(4), 850–856 (2000).
   PubMed Web of Science ®Google Scholar
• de Meester A, Carbutti G, Gabriel L, Jacques JM. Fatal overdose with trazodone: case report and literature review. Acta Clin. Belg.56(4), 258–261 (2001).
   PubMed Web of Science ®Google Scholar
• Panitch HS, Thisted RA, Smith RA et al. Pseudobulbar affect in multiple sclerosis study group. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann. Neurol.59(5), 780–787 (2006).
   PubMed Web of Science ®Google Scholar
• Kushner DJ, Baker A, Dunstall TG. Pharmacological uses and perspectives of heavy water and deuterated compounds. Can. J. Physiol. Pharmacol.77(2), 79–88 (1999).
   PubMed Web of Science ®Google Scholar
• Das MK, Ghosal SK. Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. Acta Pol. Pharm.65(4), 481–486 (2008).
   PubMedGoogle Scholar
• Knight AR, Misra A, Quirk K et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch. Pharmacol.370(2), 114–123 (2004).
   PubMed Web of Science ®Google Scholar
• Marcoli M, Maura G, Tortarolo M, Raiteri M. Trazodone is a potent agonist at 5-HT2C receptors mediating inhibition of the N-methyl-D-aspartate/nitric oxide/cyclic GMP pathway in rat cerebellum. J. Pharmacol. Exp. Ther.285(3), 983–986 (1998).
   PubMedGoogle Scholar
• Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol.340(2–3), 249–258 (1997).
   PubMed Web of Science ®Google Scholar
• McMillen BA, Walter S, Williams HL, Myers RD. Comparison of the action of the 5-HT2 antagonists amperozide and trazodone on preference for alcohol in rats. Alcohol11(3), 203–206 (1994).
   PubMedGoogle Scholar